Business Wire

MA-EVALUATE

4.6.2019 14:02:06 CEST | Business Wire | Press release

Share
Innovation and Unmet Need Drive Prescription Drug Sales to $1.18tr by 2024: New Report from Evaluate Ltd

The $1.18tr forecast for the 2024 global prescription drug market reflects the role new technologies will play in addressing unmet medical needs, as strong expectations for immuno-oncology products and emerging cell and gene therapies drive growth. In 2018, new molecule approvals from the FDA reached their highest level in over a decade, and the projected CAGR of 6.9% from 2019-2024 significantly outpaces the 2.3% CAGR seen from 2010-2018.

Growth Drivers:

  • 2018 saw 62 FDA approvals for novel drugs, an increase over the 55 approvals in 2017
  • Oncology therapies to reach $237bn in 2024, with a CAGR of 11.4%
  • Orphan Drugs will contribute an additional $109bn in sales in 2024, compared to 2018

However, as more new technologies reach the market, drug pricing pressure may continue to intensify and dampen the overall sales outlook. R&D spending is also forecast to grow more slowly from 2019-2024 than in prior years, and decrease as a proportion of overall sales – a sign of either increasing R&D efficiency, or of companies focusing on smaller indications with lower clinical development costs.

Growth Brakes:

  • $198bn in sales are at risk between 2019 and 2024, due to patent expirations
  • Anti-rheumatics sales decline as Humira, Enbrel and Remicade face competition
  • R&D as a proportion of prescription sales is forecast to decline from 21.6% in 2018 to 18% in 2024

“Scientific advancements and health technologies are converging to deliver new options for patients, while challenging traditional drug development and commercialisation models,” said report author Ryan Waters. “The question is, which companies are best poised to take advantage of the evolving pharmaceutical market?”

Top Performers:

  • Pfizer will be the leading prescription drug company in 2024, with projected sales of $51.2bn
  • Keytruda is forecast to be the top selling drug in 2024, as Humira slips in the face of biosimilars
  • Johnson & Johnson overtakes Roche to be the biggest spender on pharmaceutical R&D in 2024

Download your complimentary copy of the “EvaluatePharma® World Preview 2019, Outlook to 2024” at https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024 , or visit us at Booth #2243 at the BIO International Convention, June 3-6, in Philadelphia, PA.

About Evaluate Ltd.

Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries. Our EvaluatePharma® and EvaluatePharma Vision online subscription services provide a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.

Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.

Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com .

Follow us on Twitter: @EvaluatePharma, @Vantageanalysis

Contact:

Media Contact: Evaluate and Vantage Jennifer Dinkel +1 617-936-7783 jennifer.dinkel@evaluate.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Santander Financial Crime Transformation Leader Joins ThetaRay to Drive Enterprise AI Adoption7.7.2026 10:00:00 CEST | Press release

As Chief Strategic Customers Officer, former Group VP Luis Pinedo will scale ThetaRay’s AI compliance infrastructure across global banks, payment providers and financial institutions. ThetaRay, a leader in AI infrastructure for financial crime compliance, today announced the appointment of Luis Pinedo as Chief Strategic Customers Officer. Previously Pinedo was Group VP of Compliance at Santander Bank, where during his 16-year tenure, he led global Financial Crime Compliance (FCC) transformation initiatives across operating models, processes, and technology platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707359150/en/ Luis Pinedo joins ThetaRay as Chief Strategic Customers Officer. In his new role, Pinedo will bring key perspectives from tier-one banking operational challenges to ThetaRay’s product development and design. He will lead strategic customer engagement as well as product strategy across ThetaRay’s ent

Robbyant Unveils LingBot-Depth 2.0 and LingBot-Vision to Redefine Robotic Spatial Perception7.7.2026 09:54:00 CEST | Press release

Robbyant, an embodied AI company within Ant Group, today announced the launch of LingBot-Depth 2.0, a next-generation spatial perception model, alongside its foundational visual model, LingBot-Vision. This release marks a significant leap in robotic spatial perception, empowering robots to accurately understand and navigate the physical world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806935/en/ LingBot-Depth 2.0 reconstructs complete and planar 3D structures in challenging scenarios involving mirrors and glass From "Seeing" to "Seeing Accurately" Building upon the success of LingBot-Depth, which pioneered the Masked Depth Modeling (MDM) technique to resolve depth sensing challenges for transparent and reflective surfaces, LingBot-Depth 2.0 represents a massive scale-up in training data and performance. Trained on 150 million samples, the new model achieves top rankings in 12 out of 16 depth completion benchmarks.

RGI Group Strengthens Its Personal Insurance Capabilities in France Through KAPIA-RGI’s Acquisition of Cegid Assurex Solutions7.7.2026 09:30:00 CEST | Press release

RGI, a leading European provider of digital insurance platforms, announces that KAPIA-RGI, its France-based company specialised in personal insurance solutions, has acquired Cegid Assurex solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707323665/en/ This transaction marks a major milestone in the Group's development strategy in French speaking markets in Europe and further enhances its ability to support insurers, mutual insurers, provident institutions, brokers and bancassurers in their innovation and digital transformation initiatives. By integrating Cegid Assurex's expertise, talent and solutions, KAPIA-RGI consolidates its position as the reference leader in the Life Insurance, Savings, Retirement, Annuities and Provident markets. This acquisition expands its client base with more than 20 additional customers while accelerating innovation and growth in a market shaped by evolving regulation, automation and a

Bitcoin Suisse Advances Middle East Expansion, Receiving Financial Services Permission in Abu Dhabi7.7.2026 09:15:00 CEST | Press release

Premium virtual assets pioneer BTCS (Middle East) Ltd. is now fully authorized by the Financial Services Regulatory Authority (FSRA) of ADGM, enabling regulated institutional services across the UAE. Building on its position as Switzerland’s leading crypto financial services provider, Bitcoin Suisse is further accelerating its international expansion. Bitcoin Suisse Group’s subsidiary, BTCS (Middle East) Ltd. (“BTCS ME”) has received Financial Services Permission (FSP) from the Financial Services Regulatory Authority (FSRA) of ADGM, the international financial centre of Abu Dhabi, marking another significant step toward the Group’s international growth strategy becoming a leading global wealth management partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707864200/en/ Ceyda Majcen, Chief Executive Officer and SEO of BTCS ME, leads Bitcoin Suisse Group's expansion in the Middle East and brings extensive, long-standing

Alpaca Completes EEA Passporting to 29 Countries, Expanding Access to Regulated Investment Services Across Europe7.7.2026 09:00:00 CEST | Press release

Alpaca now provides regulated, localized investment services across the European Economic Area Alpaca, a global leader in brokerage infrastructure APIs, today announced that it has completed the process to passport its regulated and localized investment services across 29 countries in the EEA (European Economic Area) through its Spain-based EEA hub. The completion of EEA passporting enables Alpaca to extend the regulatory foundation established through its European entity, which is authorized and registered with Spain’s Comisión Nacional del Mercado de Valores (CNMV), across the EEA under the MiFID II framework. Together with Alpaca’s regulated UK entity, this milestone strengthens Alpaca’s ability to support fintechs, financial institutions, and enterprise partners building regulated investment products across Europe, reaching a market of nearly 500 million people. The passported countries include Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye